Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-065252
Filing Date
2024-08-05
Accepted
2024-08-05 17:24:15
Documents
78
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0210398-10q_allarity.htm   iXBRL 10-Q 1099723
2 CERTIFICATION ea021039801ex31-1_allarity.htm EX-31.1 9859
3 CERTIFICATION ea021039801ex31-2_allarity.htm EX-31.2 9789
4 CERTIFICATION ea021039801ex32-1_allarity.htm EX-32.1 3807
5 CERTIFICATION ea021039801ex32-2_allarity.htm EX-32.2 3711
  Complete submission text file 0001213900-24-065252.txt   6386917

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE allr-20240630.xsd EX-101.SCH 65459
7 XBRL CALCULATION FILE allr-20240630_cal.xml EX-101.CAL 35280
8 XBRL DEFINITION FILE allr-20240630_def.xml EX-101.DEF 311128
9 XBRL LABEL FILE allr-20240630_lab.xml EX-101.LAB 531031
10 XBRL PRESENTATION FILE allr-20240630_pre.xml EX-101.PRE 312153
81 EXTRACTED XBRL INSTANCE DOCUMENT ea0210398-10q_allarity_htm.xml XML 778937
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41160 | Film No.: 241176142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)